Moderna, Inc. ( MRNA ) shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and at-risk individuals.

What To Know: In a Phase 3 clinical trial, the new vaccine, mNEXSPIKE, showed a higher vaccine efficacy as well as a similar safety profile compared to the company’s original COVID-19 vaccine.

“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, CEO of Moderna ( MRNA ).

“COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA’s timely review and thank the entire Moderna ( MRNA ) team for their hard work and continued commitment to public health.”

Moderna ( MRNA ) expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season. The new vaccine is under review with regulators in multiple markets around the world.

See Also: Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday

MRNA Price Action: At the time of writing, Moderna ( MRNA ) stock is trading 2.73% higher at $27.28, according to data from Benzinga Pro.

Image: Shutterstock.